SCHEMBL6079092

SCHEMBL6079092

COC(=O)c1cccc(S(=O)(=O)Nc2ccc3ccc(N)cc3c2)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 6/20 0.61
AKR1C3 P42330 1/20 0.58
PLAT P00750 1/20 0.56
HSPD1 P10809 1/20 0.55
PTPN2 P17706 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPN5 P54829 1/20 0.55
HSPE1 P61604 1/20 0.55
TCF4 P15884 2/20 0.55
CTNNB1 P35222 2/20 0.55
ALDH1A1 P00352 1/20 0.52
SLC40A1 Q9NP59 1/20 0.51
POLB P06746 1/20 0.49
F2 P00734 1/20 0.48
AR P10275 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
ACLY P53396 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079129 0.87 PLAU (0.62) PLAUAKR1C3PLATHSPD1PTPN2
SCHEMBL6078558 0.81 TCF4 (0.65) PLAUPLATTCF4CTNNB1POLB
SCHEMBL7313388 0.81 PLAU (0.77) PLAUAKR1C3PLATTCF4CTNNB1
SCHEMBL6079643 0.80 ALDH1A1 (0.65) PLAUALDH1A1
SCHEMBL6078100 0.78 TCF4 (0.68) PLAUAKR1C3PLATTCF4CTNNB1
SCHEMBL8241750 0.77 TCF4 (0.64) HSPD1PTPN2PTPN1PTPN5HSPE1
SCHEMBL8369354 0.76 TCF4 (0.80) PLAUTCF4CTNNB1POLBACLY
SCHEMBL14721895 0.76 HSPD1 (0.59) PLAUAKR1C3PLATHSPD1PTPN2
SCHEMBL14659760 0.75 MEN1 (0.65) PLAUAKR1C3HSPD1PTPN2PTPN1
SCHEMBL23022349 0.75 TCF4 (0.68) PLAUPLATHSPD1PTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071231-B2 Naphthalene ureas as glucose uptake enhancers TELIK, INC. (US) 2006-07-04 US disclosed
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP disclosed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US disclosed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US disclosed
EP-1181271-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS Telik, Inc. (US) 2002-02-27 EP disclosed
WO-2000071506-A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2001-09-20 WO disclosed
WO-2000071506-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK, INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers GPR119, SLC2A8, SLC2A1 PLAU 1726/4885AKR1C3 1258/4885PLAT 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.